Observational Study of Immunotherapy with Concurrent Chemoradiotherapy for Elderly Patients 70 with Esophageal Squamous Cell Carcinoma

What this Trial Is About

This observational study focuses on elderly patients aged 70 years or older with esophageal squamous cell carcinoma ESCC. It aims to evaluate the safety and effectiveness of combining immunotherapy with concurrent chemoradiotherapy CCRT in treating this condition. The study seeks to measure outcomes such as objective response rate, overall survival, progression-free survival, disease control rate, duration of response, R0 resection rate, adverse events, and potential biomarkers that may predict treatment response. Participants received a combination of treatments including individualized radiotherapy targeting the tumor, platinum-based doublet chemotherapy administered during radiotherapy, and immunotherapy using PD-1 inhibitors like tislelizumab. This retrospective, single-arm study reviews patient outcomes from treatments given between January 2022 and March 2025. Follow-up evaluations occur every three months until disease progression or for up to two years. During the study, participants undergo regular assessments to monitor treatment response and safety. Researchers collect data on tumor response and survival outcomes as primary measures. The study includes follow-up visits every three months to assess ongoing health status and any adverse events. The total observation period extends up to two years or until disease progression, supporting a comprehensive understanding of treatment effects in this patient group.

An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma